Alcohol Health Services Research (R34 Clinical Trial Optional) | Apply Online

Frequently Asked Questions (FAQs): Alcohol Health Services Research (R34 Clinical Trial Optional) - PAR 22-157

1) What is the Alcohol Health Services Research (R34 Clinical Trial Optional) opportunity (PAR 22-157)?

This is a discretionary NIH grant funding opportunity offered through the National Institute on Alcohol Abuse and Alcoholism (NIAAA). It supports early-stage, time-limited health services research projects focused on improving how alcohol use disorder (AUD) treatment is delivered, accessed, paid for, and sustained in real-world settings.

2) What problem is this funding meant to address?

The main target is the national AUD "treatment gap" - the ongoing mismatch between the number of people who need effective AUD care and the number who actually receive it. Projects should aim to generate practical, actionable findings that can help narrow this gap.

3) What does "R34" mean in the context of this FOA?

The R34 mechanism is commonly used to pilot, refine, and test the practicality (feasibility) of approaches that may later be expanded into larger-scale studies. It is geared toward early-stage work that helps establish whether a strategy can work in routine settings and produce useful evidence for next-step research.

4) Are clinical trials required under this announcement?

No. This FOA is labeled "Clinical Trial Optional," meaning clinical trials are allowed but not required. Applicants can propose intervention-testing studies or other rigorous health services or service-system research that does not involve a clinical trial.

5) What kinds of research topics does NIAAA want to support?

NIAAA is looking for practical, real-world health services research focused on how AUD care is delivered, financed, accessed, and maintained in routine practice environments, with the goal of improving service reach, quality, and continuity.

6) What are the main emphasis areas for this funding opportunity?

NIAAA highlights five emphasis areas: (1) increasing access to AUD treatment, (2) making treatment more appealing and acceptable, (3) studying cost structures and insurance systems, (4) dissemination and implementation of evidence-based AUD approaches, and (5) reducing health disparities in AUD treatment.

7) What are examples of projects focused on increasing access to AUD treatment?

Examples mentioned in the opportunity include improving screening and referral pathways, strengthening treatment capacity, integrating AUD care into primary care or emergency settings, using telehealth to reach underserved areas, and streamlining entry into services.

8) What does it mean to make AUD treatment more "appealing and acceptable"?

This area focuses on improving patient willingness to start and continue treatment. Examples include reducing stigma, improving patient engagement, tailoring services to patient preferences, simplifying care pathways, and developing models that fit better into daily life (such as low-threshold or culturally responsive options).

9) What does the FOA say about insurance, payment, and cost-related research?

The FOA encourages research on how coverage rules, reimbursement rates, prior authorization, network design, and payment models influence whether people can start and stay in AUD care. It also highlights examining financial levers that could improve treatment uptake and continuity.

10) What does "dissemination and implementation" mean in this opportunity?

It refers to studies of how to move existing evidence-based AUD interventions into routine practice at scale. The FOA emphasizes understanding barriers to adoption, testing implementation strategies, and measuring factors like fidelity, sustainability, and system-level outcomes.

11) How does this FOA address health disparities in AUD treatment?

Reducing disparities is a priority area. The FOA explicitly focuses on improving care for health disparity populations and understanding how structural factors, geography, language, culture, discrimination, and resource gaps contribute to unequal access and outcomes.

12) What is the CFDA number associated with this opportunity?

The opportunity is listed under CFDA 93.273 (health-related research).

13) What funding instrument is used for this opportunity?

This opportunity uses the grant funding instrument.

14) What is the maximum award amount listed for this FOA?

The posted award ceiling is $450,000, which indicates an upper limit on total support under the FOA as presented in the provided details.

15) When was the closing date shown in the provided information?

The original closing date shown in the provided data is 2023-05-07.

16) Who is eligible to apply?

Eligibility is broad and includes many types of domestic organizations and government entities, such as state, county, and city governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other tribal organizations; public housing authorities; and both nonprofit and for-profit organizations (including small businesses and for-profits other than small businesses).

17) Are institutions that focus on serving specific populations explicitly included?

Yes. The FOA explicitly calls out eligibility for organizations often central to disparity-focused and community-engaged work, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISISs).

18) Are faith-based and community-based organizations eligible?

Yes. Faith-based and community-based organizations are included among eligible applicants.

19) Are U.S. territories or possessions eligible to apply?

Yes. U.S. territories or possessions are listed among eligible applicants.

20) Are federal agencies eligible to apply?

Yes. Eligible federal agencies are included among eligible applicants.

21) Are foreign (non-U.S.) organizations eligible to apply?

Yes. The provided information indicates that non-U.S. entities (foreign organizations) are included among eligible applicants.

22) What types of partners or settings fit this FOA best?

This FOA is designed for teams positioned to test solutions in real service environments. The emphasis is on routine settings where AUD care is delivered and financed, and where results can inform health systems, payers, communities, and policymakers.

23) What is the overall goal of projects funded through this opportunity?

The overall goal is to support targeted, applied research that demonstrates feasible strategies for narrowing the AUD treatment gap, improving service delivery, and producing actionable findings relevant to real-world decision-makers.

24) What makes this opportunity different from studies that focus only on clinical efficacy?

The emphasis here is on practical health services questions: how to improve access, engagement, implementation, financing, and sustainability of AUD care in everyday settings, rather than focusing only on whether a treatment works under ideal or tightly controlled conditions.

25) What kinds of outcomes does NIAAA appear to care about based on the emphasis areas?

Based on the description, outcomes of interest include improved access and entry into care, better engagement and acceptability, increased uptake and continuity influenced by financing and insurance design, improved adoption and sustainability of evidence-based practices, and measurable reductions in disparities affecting access and outcomes.